ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO207

Antibiotic Exposure and Kidney Stone Disease Across the Life Course

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Denburg, Michelle, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
  • Li, Zeyu Nancy, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Huang, Jing, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Parlett, Lauren E., HealthCore, Wilmington, Delaware, United States
  • Haynes, Kevin, Janssen Global Services LLC, Titusville, New Jersey, United States
  • Asplin, John R., LithoLink Corp, Chicago, Illinois, United States
  • Luna, Ingrid Y., The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
  • Bailey, Charles, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
  • Tasian, Gregory Edward, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Background

Kidney stone disease (KSD) is increasingly common and associated with considerable morbidity. Antibiotic (ABX) exposure may be a risk factor for KSD.

Methods

We examined the association between 12 classes of oral ABX and KSD in a case-control study nested in the HealthCore Integrated Research Database (HIRD) of longitudinally integrated medical and pharmacy claims from healthcare encounters of members with ≥6 months of continuous enrollment in commercial health plans across the United States from Jan 2006 to Jan 2020. Incidence density sampling was used to match cases 4-65 years of age at initial KSD diagnosis to up to 5 controls on year of birth, index date, pre-index enrollment time, sex, and geographic region. Exclusion criteria were inflammatory bowel disease, celiac disease, urinary obstruction, bariatric surgery, malignancy, cystic fibrosis, immobility, and neurogenic bladder. Conditional logistic regression models were stratfied at age 18 and adjusted for other ABX use, healthcare utilization, comorbidities, UTI, thiazide and loop diuretics, H2 blockers, proton-pump inhibitors, statins, corticosteroids, and certain anti-epileptic agents.

Results

69,793 children (11,622 cases/58,171 controls; 59.9% female) and 2,990,207 adults (498,393 cases/2,491,814 controls; 43.6% female) were included. Exposure to any of the 12 ABX classes in adults and 8 different ABX classes in children within 3-12 months prior to index was associated with KSD at the Bonferroni adjusted significance threshold (Table). The magnitude of association was greatest for fluoroquinolone, nitrofurantoin, and sulfa ABX with adjusted OR of 1.37-1.66 and similar effect estimates in sensitivity analyses excluding those with UTI during the exposure window and restricting to cases who had KSD surgery on or aftex index and their controls.

Conclusion

Leveraging a large claims database, we confirmed that exposure to oral ABX is associated with KSD diagnosis in children and adults.

Odds of KSD according to ABX class in children and adults

Funding

  • NIDDK Support